| Literature DB >> 33477676 |
Matteo Santoni1, Francesco Massari2, Sergio Bracarda3, Giuseppe Procopio4, Michele Milella5, Ugo De Giorgi6, Umberto Basso7, Gaetano Aurilio8, Lorena Incorvaia9, Angelo Martignetti10, Mimma Rizzo11, Giacomo Cartenì12, Enrique Grande13, Marc R Matrana14, Simon J Crabb15, Nuno Vau16, Giulia Sorgentoni1, Alessia Cimadamore17, Rodolfo Montironi17, Nicola Battelli1.
Abstract
We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves. Cox proportional models were used at univariate and multivariate analyses. We collected data from 224 patients with advanced RCC receiving cabozantinib as second- (113, 5%) or third-line (111, 5%) therapy. The median PFS was significantly higher in patients with BMI ≥ 25 (9.9 vs. 7.6 months, p < 0.001). The median OS was higher in the BMI ≥ 25 subgroup (30.7 vs. 11.0 months, p = 0.003). As third-line therapy, both median PFS (9.2 months vs. 3.9 months, p = 0.029) and OS (39.4 months vs. 11.5 months, p = 0.039) were longer in patients with BMI ≥ 25. BMI was a significant predictor for both PFS and OS at multivariate analysis. We showed that a BMI ≥ 25 correlates with longer survival in patients receiving cabozantinib. BMI can be easily assessed and should be included in current prognostic criteria for advanced RCC.Entities:
Keywords: body mass index; cabozantinib; obesity; prognosis; real-world data; renal cell carcinoma; targeted therapy
Year: 2021 PMID： 33477676 PMCID： PMC7831923 DOI： 10.3390/diagnostics11010138
Source DB: PubMed Journal: Diagnostics (Basel) ISSN： 2075-4418